Welcome to MOMA, where innovation meets precision in the quest for groundbreaking treatments.
Molecular
Machines
Our mission is simple yet profound: to harness the power of highly dynamic proteins and forge a new era of precision therapeutics, initially focusing on oncology.
The MOMA team is committed to turning groundbreaking science into meaningful treatments for patients. Every discovery, every innovation, is more than a scientific pursuit—it’s an opportunity to change lives.
What are highly dynamic proteins?
Highly dynamic proteins are enzymes that convert chemical energy stored in our cells into process-regulating tasks like protein transport and degradation, DNA unwinding, inflammatory response activation and cell death. When misdirected, they play a central role in the progression of many diseases including cancer, autoimmune, neuroscience and cardiovascular (CV) conditions.
This class is difficult to drug because of their dynamic motion and unyielding ability to shape shift. However, an ever-expanding understanding of these cell laborers’ mechanics is paving the way for innovative therapeutic approaches.
Several marketed drugs target highly dynamic proteins— mevacamten for CV diseases, ivacaftor for cystic fibrosis and omeprazole for acid reflux—but most were discovered by serendipity or as one-off R&D efforts. MOMA is doing it differently.
Our scientific approach is targeted and precise.
Across a range of tumors, cancer cells often depend on these highly dynamic proteins. At MOMA, our pipeline is zeroing in on these dependency to disrupt the disease’s lifeline and offer new hope where existing treatment options may fall short.
Our scientific approach is targeted and precise.
Across a range of tumors, cancer cells often depend on these highly dynamic proteins. At MOMA, our pipeline is zeroing in on these dependency to disrupt the disease’s lifeline and offer new hope where existing treatment options may fall short.
Why are we unique?
The MOMA team comprises world-class researchers and other industry experts. Together, we are unapologetically scientific in our shared passion to push the boundaries of what is possible and unlock the potential of highly dynamic proteins.
Our organization is purpose-built and laser-focused on tackling the unique challenges and opportunities inherent to this drug class. What sets MOMA apart is our fully integrated approach to therapeutic discovery that unites cutting-edge technologies with a deep understanding of biological systems, enabled through a proprietary drug discovery platform.
About our platform
MOMA’s bespoke KNOMATIC™ platform integrates structural insights, hit finding technologies and computational lead optimization to accelerate life-changing therapies.
Each component of the KNOMATIC™ platform is developed and optimized for the sole purpose of drugging highly dynamic proteins.
Interwoven with powerful machine learning, our platform leverages advanced structural frameworks and functional genomics insights to identify and validate new targets.
Sophisticated methodologies enabled by artificial intelligence, high throughput fragment and DEL screening, and CRISPR-based gene editing discern dynamic motion and structure patterns. This allows us to predict hit-finding outcomes and rapidly prioritize lead optimization with staggering accuracy. From there, our platform enables the rapid prioritization of lead compounds—ultimately streamlining the path to clinical development.
Our knowledge base
MOMA leadership made an early and intentional decision to build our platform to an unprecedented scale, with an unparalleled ability to harness big data. A its core is a constantly growing knowledge base, the epitome of our trailblazing ethos that allows us to refine the drug discovery process to a previously unattainable degree of precision.
Our platform’s streamlined workflows and directed activities are constantly increasing in sophistication and efficiency, fed by new research insights and outcomes. This significantly reduces the time and cost associated with drug discovery, while also predicting drug-target interactions with the highest probability of success.
Our Pipeline
Our platform has generated a strong pipeline of high values targets
Explore Our PipelineScientific breakthroughs
MOMA has evolved from a visionary start-up to a beacon of drug discovery and clinical prowess. We have leapt from theory to therapy, with our first oncology program entering Phase 1 in 2024 and our second lead oncology asset anticipated to enter the clinic in early 2025.
A rich portfolio of novel pre-clinical candidates follows behind our lead assets. Our pipeline is not just a promise, but a continuous surge of innovation as we realize the potential of highly dynamic medicines. MOMA is transforming drug discovery for precision oncology therapeutics—and beyond.